Neurotech International (NTI) has updated the ASX on the development of its proprietary formulation for the treatment of multiple sclerosis (MS).

NTI said results from an in-vitro study conducted in conjunction with Melbourne’s RMIT University showed its NTI/Dolce Strains suppressed the production of two key inflammatory neuro-markers involved in MS by 40% and 30% respectively. CBD alone had no significant effect.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.